CAMBRIDGE, Mass., Feb. 28, 2017 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC), a leader in discovering
and developing targeted kinase medicines for patients with
genomically defined diseases, today announced its
participation in the following upcoming investor conferences:
- Cowen and Company 37th Annual Health Care Conference in
Boston, MA on Tuesday, March 7, 2017 at 10:00 a.m. E.T.
- Oppenheimer 27th Annual Healthcare Conference in
New York, NY on Wednesday, March 22, 2017 at 11:30 am. E.T.
A live webcast of each presentation will be available by
visiting the Investors section of Blueprint
Medicines' website at http://ir.blueprintmedicines.com. A
replay of the webcast will be archived on Blueprint
Medicines' website for 30 days following each
presentation.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of
targeted and potent kinase medicines to improve the lives of
patients with genomically defined diseases. Its approach is rooted
in a deep understanding of the genetic blueprint of cancer and
other diseases driven by the abnormal activation of
kinases. Blueprint Medicines is advancing four clinical
trials for subsets of patients with gastrointestinal stromal
tumors, hepatocellular carcinoma, systemic mastocytosis, non-small
cell lung cancer and medullary thyroid cancer, as well as multiple
programs in research and preclinical development. For more
information, please visit www.blueprintmedicines.com .
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-in-march-300414648.html
SOURCE Blueprint Medicines